Rajinder Dawra

Dr. Rajinder Dawra


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Gastroenterology
Verified
Journal Article
Open access
PDF file
VDVikas Dudeja
Vikas Dudeja
NMNameeta Mujumdar
Nameeta Mujumdar
APand Phoebe A. Phillips
and Phoebe A. Phillips
RCRohit Chugh
Rohit Chugh
DBDaniel Borja–Cacho
Daniel Borja–Cacho
ASAshok K. Saluja
Ashok K. Saluja
Background & Aims Heat shock proteins (HSPs) are highly conserved and serve a multitude of functions that mediate cell survival. HSP70, the only inducible form of the 70-kilodalton subfamily of HSPs, is overexpressed in pancreatic cancer cells and has been shown to inhibit caspase-dependent apoptosis. We aimed to elucidate the mechanism by which HSP70 inhibits apoptosis in cancer cells. Methods HSP70 expression was down-regulated in cultured pancreatic cancer cells by exposure to quercetin, triptolide, or short interfering RNAs. Intracellular Ca2+, cytosolic cathepsin B activity, caspase-3 activity, cell viability, and lysosome integrity were measured using colorimetric assays. Immunofluorescence assays were used to localize cathepsin B and Lamp2. BAPTA-AM was used to chelate intracellular Ca2+. Results Inhibition of HSP70 increased intracellular Ca2+ levels in pancreatic and colon cancer cell lines and led to loss of lysosome integrity in pancreatic cancer cells. The release of intracellular Ca2+ and lysosomal enzymes activated caspase-dependent apoptosis independently and simultaneously. Conclusions HSP70 inhibits apoptosis in cancer cells by 2 mechanisms: attenuation of cytosolic calcium and stabilization of lysosomes. HSP70-mediated cell survival might occur in other types of cancer cells.

19 September 2023 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
HIHASSAN MUBARAK ISHQI
HASSAN MUBARAK ISHQI
MAMisha Ali
Misha Ali
RDRajinder Dawra
Rajinder Dawra

25 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
EBEjas Palathingal Bava
Ejas Palathingal Bava
JGJohn George
John George
MTMohammad Tarique
Mohammad Tarique
SISrikanth Iyer
Srikanth Iyer
PSPreeti Sahay
Preeti Sahay
VDVikas Dudeja
Vikas Dudeja
Despite decades of research, there is no specific therapy for acute pancreatitis (AP). In the current study, we have evaluated the efficacy of pirfenidone, an antiinflammatory and antifibrotic agent that is approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF), in ameliorating local and systemic injury in AP. Our results suggest that treatment with pirfenidone in therapeutic settings (e.g., after initiation of injury), even when administered at the peak of injury, reduces severity of local and systemic injury and inflammation in multiple models of AP. In vitro evaluation suggests that pirfenidone decreases cytokine release from acini and macrophages and disrupts acinar-macrophage crosstalk. Therapeutic pirfenidone treatment increases IL-10 secretion from macrophages preceding changes in histology and modulates the immune phenotype of inflammatory cells with decreased levels of inflammatory cytokines. Antibody-mediated IL-10 depletion, use of IL-10–KO mice, and macrophage depletion experiments confirmed the role of IL-10 and macrophages in its mechanism of action, as pirfenidone was unable to reduce severity of AP in these scenarios. Since pirfenidone is FDA approved for IPF, a trial evaluating the efficacy of pirfenidone in patients with moderate to severe AP can be initiated expeditiously.

24 August 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HJHarrys Kishore Charles Jacob
Harrys Kishore Charles Jacob
Rossana SignorelliRossana Signorelli
Rossana Signorelli
John Lalith Charles RichardJohn Lalith Charles Richard
John Lalith Charles Richard
TKTyler Kashuv
Tyler Kashuv
SLshweta Lavania
shweta Lavania
ASAshok Saluja
Ashok Saluja
Background: Pancreatic cancer is one of the most difficult cancers to detect early and most patients die from complications arising due to distant organ metastases. The lack of bona fide early biomarkers is one of the primary reasons for late diagnosis of pancreatic cancer. It is a multifactorial disease and warrants a novel approach to identify early biomarkers. Methods: In order to characterize the proteome, Extracellular vesicles (EVs) isolated from different in vitro conditions mimicking tumor-microenvironment interactions between pancreatic cancer epithelial and stromal cells were analyzed using high throughput mass spectrometry. The biological activity of the secreted EVome was analyzed by investigating changes in distant organ metastases and associated early changes in the microbiome. Candidate biomarkers (KIF5B, SFRP2, LOXL2, and MMP3) were selected and validated on a mouse-human hybrid Tissue Microarray (TMA) that was specifically generated for this study. Additionally, a human TMA was used to analyze the expression of KIF5B and SFRP2 in progressive stages of pancreatic cancer. Results: The EVome of co-cultured epithelial and stromal cells is different from individual cells with distinct protein compositions. EVs secreted from stromal and cancer cells cultures could not induce significant changes in Pre-Metastatic Niche (PMN) modulation, which was assessed by changes in the distant organ metastases. However, they did induce significant changes in the early microbiome, as indicated by differences in α and β-diversities. KIF5B and SFRP2 show promise for early detection and investigation in progressive pancreatic cancer. These markers are expressed in all stages of pancreatic cancer such as low grade PanINs, advanced cancer, and in liver and soft tissue metastases. Conclusions: Proteomic characterization of EVs derived from mimicking conditions of epithelial and stromal cells in the tumor-microenvironment resulted in the identification of several proteins, some for the first time in EVs. These secreted EVs cannot induce changes in distant organ metastases in in vivo models of EV education, but modulate changes in the early murine microbiome. Among all the proteins that were analyzed (MMP3, KIF5B, SFRP2, and LOXL2), KIF5B and SFRP2 show promise as bona fide early pancreatic cancer biomarkers expressed in progressive stages of pancreatic cancer.

7 May 2022 in Pancreatology
Verified
Journal Article
Closed access
EBEjas Palathingal Bava
Ejas Palathingal Bava
JGJohn George
John George
SISrikanth Iyer
Srikanth Iyer
PSPreeti Sahay
Preeti Sahay
MTMohammad Tarique
Mohammad Tarique
VDVikas Dudeja
Vikas Dudeja

16 December 2021 in Pancreatology
Verified
Journal Article
Closed access
JTJunyi Tao
Junyi Tao
HCH. Cheema
H. Cheema
KKK. Kesh
K. Kesh
VDV. Dudeja
V. Dudeja
RDRajinder Dawra
Rajinder Dawra
SRSabita Roy
Sabita Roy